News & analysis on the clinical development and manufacture of large molecule drugs
Cereval, Tony Coles
By Ben Hargreaves
- Last updated on
Tony Coles is drafted in to take the leadership position at Cereval Therapeutics, which is looking to progress clinical and preclinical drug candidates to treat neurodegenerative disorders. The biotech was formed through the combination of Pfizer’s pipeline and Bain Capital’s investment.
Coles will become CEO of the biotech, which is based in the Greater Boston area, in the US, after having previously worked at the company as executive chairperson since December 2018.
Prior to joining Cereval, Coles had been a co-founding investor and CEO at Yumanity Therapeutics, which is similarly focused on developing treatments for neurodegenerative disorders, such as Parkinson’s and Alzheimer’s disease. He was also CEO of Onyx Pharmaceuticals, which was acquired by Amgen, and CEO of NPS Pharmaceuticals.
Adam Koppel, managing director of Bain Capital Life Sciences and a member of the board of directors of Cerevel Therapeutics, said, “The board of directors were unanimous in our belief that given his track record of success, Coles was the right person to lead the organization as we aggressively pursue the development of transformative solutions to treat neuroscience diseases.”